Associated Nephrology Consultants Header Logo
// console.log("Selected value: " + selectedValue);

Exciting Opportunities in Kidney Research at ANC

ANC Team

-

October 14, 2024

Exciting Opportunities in Kidney Research at ANC

ANC’s Clinical Trial Research

Here at ANC, we are thrilled to announce our participation in global clinical trials focused on
developing new treatments for people with kidney disease. We are partnering with Davita
Clinical Research to bring opportunities for our patients to have access to developing, cutting-
edge treatments early on and we are excited to share this opportunity with you and anyone
affected by kidney disease.

Historically, participation in impactful research was often limited to very large practices and well-
funded institutions far away from the Twin Cities. Now, as interest grows and more resources
become available for studies in kidney disease, ANC and our partners at Intermed Consultants
bring opportunities to our patients close to home.

 

Key Studies at ANC and Intermed Consultants

(1) Hyperparathyroidism in Dialysis Patients

One study participating in focuses on hyperparathyroidism in dialysis patients.
Hyperparathyroidism is a complication in dialysis patients where over-activity of the parathyroid
glands leads to bone disease. This trial takes place in our dialysis units and aims to improve
calcium-phosphate balance in the body and prevent common dialysis complications.

 

(2) Therapies for Specific Glomerular Diseases

We are recruiting for several studies of glomerular diseases which cause inflammation in kidney
filters and can lead to kidney failure. In the past, we did not have good treatments for some of
these diseases but now there’s been a lot of research, and promising new treatments have
been developed. If you or someone you know has IgA Nephropathy, Focal Sclerosis, or
Membranous Nephropathy, you may be eligible for a new drug trial.

 

(3) Genetic Chronic Kidney Disease (CKD)

We are recruiting for a new study for patients with a genetic abnormality that raises the risk of
severe kidney disease. Though 10% of the U.S. population is African American, they make up
nearly 30% of dialysis patients. Abnormalities in the APOL1 gene are thought to be common in
these individuals and explain much of the high incidence of severe kidney disease in African
Americans. There is an open study testing a new drug in patients with this genetic marker. If
you are interested, screening for this gene is offered at no cost. For individuals with this genetic
marker, there is a new treatment being tested to prevent kidney damage in patients with
abnormal APOL1 variants.

 

Getting Involved

If you or someone you know is interested in more information on time commitment, trial
protocols, and compensation or participating in a clinical trial, call us.

ANC Team

Subscribe Our Newsletter for more helpful tips

Subscription Form

Our Blogs

Nephrology team at ANC creating a personalized kidney care plan with a patient.
Personalized Kidney Care Plans: Why One-Size Doesn't Fit All
- September 10, 2025
Patient meeting with nephrology team at ANC clinic in Minneapolis-St. Paul.
Finding the Right Nephrologist in St. Paul and Minneapolis: A Patient Guide
- September 10, 2025
Patient discussing long-term kidney health plan with ANC nephrology team in Minnesota.
How Comprehensive Nephrology Services Improve Long-Term Kidney Health
- September 10, 2025
Patient receiving dialysis care at ANC-affiliated clinic in Minneapolis.
Dialysis Care in Minneapolis: What Patients and Families Can Expect
- September 10, 2025
A patient meeting with a nephrologist at ANC in Minnesota to discuss how hypertension affects kidney health.
The Role of Nephrology in Hypertension and Kidney Health
- September 10, 2025
Patient meeting with a nephrology team at Associated Nephrology Consultants in Minnesota to review PKD treatment plans.
Polycystic Kidney Disease Treatment Options in Minnesota Explained
- September 10, 2025